Table 3.

Association of MGMT gene expression with clinically-defined AD and AD-related neuropathologic traits in ROSMAP.

Subjects	Phenotype	N	Beta	SE	P-value
All	AD status	261	−0.08	0.07	0.24
	NFT	601	−0.17	0.05	0.00059
	ptau	595	−0.36	0.12	0.0034
	Abeta	595	−0.25	0.07	0.00078
Women	AD status	179	−0.12	0.09	0.15
	NFT	385	−0.18	0.06	0.0036
	ptau	381	−0.33	0.15	0.02
	Abeta	381	−0.23	0.09	0.0087
ε4- Women	AD status	131	−0.14	0.09	0.15
	NFT	289	−0.24	0.06	0.00032
	ptau	288	−0.34	0.16	0.03
	Abeta	288	−0.20	0.10	0.05
ε4+ Women	AD status	48	0.01	0.18	0.94
	NFT	96	−0.01	0.15	0.93
	ptau	93	−0.29	0.32	0.36
	Abeta	93	−0.30	0.15	0.04
Men	AD status	82	0.01	0.13	0.95
	NFT	216	−0.15	0.08	0.07
	ptau	214	−0.38	0.22	0.09
	Abeta	214	−0.31	0.13	0.02
ε4- Men	AD status	59	−0.04	0.15	0.77
	NFT	159	−0.14	0.07	0.06
	ptau	158	−0.47	0.23	0.04
	Abeta	158	−0.41	0.16	0.01
ε4+ Men	AD status	23	−0.08	0.21	0.69
	NFT	57	−0.13	0.21	0.55
	ptau	56	0.01	0.52	0.98
	Abeta	56	0.11	0.20	0.60

Effect = effect estimate; SE = standard error; significant results (P_adjusted < 0.0042) are in bold.